eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank

 
6/2020
vol. 16
 
Share:
Share:
more
 
 
Electrophysiology
Clinical research

Cerebral microembolism during atrial fibrillation ablation can result from the technical aspects and mostly does not cause permanent neurological deficit

Anetta Lasek-Bal
1
,
Przemysław Puz
1
,
Joanna Wieczorek
2
,
Seweryn Nowak
2
,
Anna Maria Wnuk-Wojnar
2
,
Aldona Warsz-Wianecka
1
,
Katarzyna Mizia-Stec
2

1.
Department of Neurology, School of Health Sciences, Medical University of Silesia, Katowice, Poland
2.
First Department of Cardiology, School of Medicine, Medical University of Silesia, Katowice, Poland
Arch Med Sci 2020; 16 (6): 1288–1294
Online publish date: 2020/04/25
Article file
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Introduction

Atrial fibrillation ablation is a recognized invasive method of treatment involving pulmonary vein isolation (PVI). The procedure performed within the left atrium using the insertion of electrodes by trans-septal puncture can be associated with the risk of acute neurological incidents despite anticoagulation [13]. In the majority of patients, ultrasound monitoring of the blood flow in the middle cerebral arteries during PVI exhibits microembolic signals (MES) which are usually clinically asymptomatic both during detection and over short-term follow-up. However, 5–40% of patients in the periprocedural period reported acute vascular lesions in diffusion-weighted magnetic resonance imaging (DW-MRI, DWI) of the head [412]. Lesion morphology indicates an embolic, probably cardiogenic etiology. The presence of foci in DWI proves that MES can be manifested by means of radiology. To date, no studies have been carried out to evaluate the further evolution of MES. Although the significance of MES or foci in head DWI has not been established in the periprocedural period, some authors indicate a possible negative effect of MES during ablation on patients’ cognitive functions [3, 10]. Evaluation of the procedure’s safety is significant due to increasing numbers of ablations performed also in patients with multiple morbidities. Differences were demonstrated in the amount of recorded MES depending on the type of ablation; MES were significantly more frequent during standard radiofrequency (RF) PVI than during cryoballoon ablation [5, 6, 13]. It is conceivable that different types of atrial fibrillation ablation are associated with a different risk of acute neurological incidents [1, 3, 5, 6, 1218].

The aims of this study were to perform quantitative and a qualitative evaluation of MES during PVI and establish the potential significance of MES for damage of the brain assessed in radiological investigation and the neurological state of patients. Using the magnetic resonance technique, lesions of vascular origin were evaluated in patients before and up to a few months following the procedure. Ultrasound and radiological analyses were performed along with monitoring patients’ neurological status.

Material and methods

The project was conducted as a prospective analysis. Patients with AF undergoing percutaneous PVI (radiofrequency ablation/balloon cryoablation) during scheduled hospitalization in the First Department of Cardiology, Medical University of Silesia were enrolled in the study group. Patients with paroxysmal and persistent AF, with no history of brain stroke or transient ischemic attack (TIA), were also included. The medical information was based on the tests and specialist consultations performed during hospitalization and/or the analysis of patients’ previous medical records. Other eligibility criteria were: no prior ablation due to atrial fibrillation (AF), left ventricular ejection fraction (LVEF) > 50%, no significant hemodynamic stenosis of the carotid (≥ 70%) and/or cerebral artery (≥ 50%) based on the result of duplex ultrasound with Doppler imaging. The exclusion criteria were: lack of adequate anticoagulation in the month preceding the procedure, prior ischemic or hemorrhagic stroke, venous or arterial thromboembolism, an estimated glomerular filtration rate < 60 ml/min/1.73 m2, pregnancy and age < 18 and > 80. We used the CHA2DS2VASc scale to estimate the annual burden of stroke. All patients were anticoagulated with vitamin K antagonists for at least one month prior to PVI, confirming once a week adequate anticoagulation in the month preceding the procedure. All patients underwent transesophageal echocardiography (TEE) in order to exclude the presence of LA appendage thrombus within 24 h prior to the procedure. Three or four venous accesses were obtained using the Seldinger technique – one for the left (6 Fr sheath – quadripolar electrode placed in the right ventricle) and right femoral vein (two 8 Fr sheathes – circular mapping and radiofrequency ablation electrodes or one 14 Fr for cryoablation balloon) and the right jugular vein (6 Fr sheath – decapolar electrode coronary sinus catheterization) (stage 1). Rotational angiography of the left atrium was performed at the beginning of the procedure (contrast medium injection into the pulmonary artery during rapid right ventricular stimulation). Trans-septal puncture was the next step of the procedure (stage 2). Following trans-septal puncture, 3-dimensional electro-anatomical mapping was performed in patients undergoing radiofrequency ablation using the CARTO 3 system (Biosense Webster, Diamond Bar, CA, USA). PVI was achieved by means of either (n = 72, 90%) radiofrequency (RF) ablation with the ThermoCool SmartTouch SF catheter (Biosense Webster, Diamond Bar, CA, USA) or balloon cryoablation (n = 8, 10%) using an Arctic Front Advance catheter (Medtronic, MN, USA) (stage 3).

Radiofrequency PVI ablation was performed with 30 W energy (reduction to 25 W in the posterior wall). The energy application in one spot was about 30 s with dragging to another for about 3– 4 mm for the next 30 s circumferentially around all pulmonary veins. Isolation was defined as an entrance/exit block observed in a circular mapping electrode in every pulmonary vein. No steam pop was observed in patients treated using the workflow.

The final stage was the removal of devices outside the circulatory system (stage 4). PVI was performed under the guidance of a circular mapping electrode – Lasso (Biosense Webster, Diamond Bar, CA, USA) or Achieve catheter (Medtronic, MN, USA). The procedure was performed with an INR of up to 2.5 (preferably 2.0–2.5).

All patients received an IV bolus of unfractionated heparin (100 IU/kg) immediately after the trans-septal puncture and continuous infusion of 2000 IU/h through a trans-septal sheath in order to obtain an activated clotting time (ACT) time result above 300 s. ACT time was measured at 30-minute intervals during the procedure. Post-procedural 24-hour heparin infusion as per activated clotting time was continued only in patients with an international normalized ratio (INR) < 2 during the procedure (lowest INR value: 1.8). Another vitamin K antagonist dose was administered 4 h after the procedure in order to obtain an INR within the range of 2.0–3.0 on the following day. Informed consent was obtained from each patient and the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a prior approval by the institution’s human research committee. The project was accepted by the Bioethical Committee, Medical University of Silesia in Katowice (No. KNW/0022/KB1/72/13).

Microembolic signal detection

MES monitoring was carried out throughout the entire procedure: from the moment of large vessel puncture to the moment of device withdrawal. The right middle cerebral artery (MCA) was continuously insonated through a temporal bone window at a depth of 48–56 mm using a 2 MHz probe, the Pioneer 2020. Embolic signals were evaluated by two independent observers in accordance with the established criteria [3, 19, 20]. Quantitative evaluations of MES were applied: grade I: 1–10 MES, grade II: 11–30 and MES- curtain: > 30 signals [20]. An automated algorithm was used to differentiate between the gaseous and solid MES. The quantitative analysis was performed considering the procedure’s division into four stages, as presented above.

Magnetic resonance imaging (MRI) of the head

The patients observed had their head MRIs performed twice: before and after ablation, with the maximum period between these tests being 12 months. The T2, FLAIR, SWI and DWI sequences were used to evaluate the lesions of vascular origin. The Fazekas scale (FS) was used to analyze the lesions in the white matter [21, 22]. The modified Fazekas scale ranges from mild to severe. Mild white matter hyperintensities (WMH) (grade 1) was defined by punctate lesions in the deep white matter with a maximum diameter of 9 mm for a single lesion and of 20 mm for grouped lesions. Moderate WMH (grade 2) were early confluent lesions of 10–20 mm single lesions and > 20 mm grouped lesions in any diameter, and no more than connecting bridges between the individual lesions. Severe WMH (grade 3) were single lesions or confluent areas of hyperintensity of ≥ 20 mm in any diameter.

Screening cognitive examination

A neurology examination on each patient was carried out three times by neurologists: on the day of ablation and on the days of head MRIs. The Mini Mental State Examination Scale was performed twice, during the qualification and the last neurological examination [23].

Statistical analysis

For the description of parametric data, the mean, standard deviation, median, minimum and maximum value of a given variable in the study group were calculated. To characterize non-parametric data, the number of occurrences of the variable in the study group and the percentage of these occurrences were used.

Results

Eighty-eight patients were initially enrolled in the study; however, for technical reasons, the signal from MCA, which would have enabled us to analyze potential embolic signals, could not be obtained in 8 patients. Thus, the study enrolled 80 patients at a mean age of 58 years. The mean CHA2DS2VASc score for the study group was 2 and indicated a low risk of embolic cardiovascular events in a 1-year follow-up. In the majority of patients, head MRIs did not reveal any vascular brain damage. The results of the screening cognitive function examination showed normal status in all patients. The demographic, clinical and radiological data of the patients are presented in Table I.

Table I

Demographic and clinical features of patients

ParameterValue
Age, mean (range)58 (50–63)
Sex F/M, n 30/50
AF duration [years], n (%):
 0–537 (46)
 6–1027 (34)
 > 1016 (20)
Functional classification by EHRA3 (2–3)
CHA2DS2-Vasc risk scale, mean (range)2 (0–4)
CHD, n (%)15 (19)
AH, n (%)56 (70)
DM, n (%)15 (19)
LD, n (%)55 (69)
Obesity, n (%)27 (34)
PAD, n (%)22 (18)
WMH, n (%):
 0–167
 2–313
MMSE29 (27–30)

[i] F – female, M – male, AF – atrial fibrillation, EHRA – European Heart Rhythm Association, CHD – coronary heart disease, AH – arterial hypertension, DM – diabetes mellitus, LD – lipid disorders, PAD – peripheral artery disease, WMH – white matter hyperintensities.

Microembolic signals

Microembolic signals during the monitoring of the flow in the right MCA were recorded in 61 (76.25%) patients in the amount of 51–489 (mean: 239). Most often these were registered during the 2nd and 3rd stage, most rarely during stage 1. In the majority of patients (89%), MES were gaseous in nature (Table II, Figure 1). The distribution of volume-MES analysis results was as follows: 1–10 MES in 21 (33.43%) patients, 11–30 in 34 (55.73%) and MES- curtain (> 30 signals) in 6 (10.84%) patients.

Table II

Characteristics of microembolic signals

ParameterN (patients)N (MES)
MES, mean (min.–max.); med.61263.6 ±117.9
(51–489); 239
Stage 1 (min.–max.); med.141.64 ±0.93
(1–4); 1.0
Stage 2 (min.–max.); med.61136.4 ±73.9
(25–312); 111
Stage 3 (min.–max.); med.50102.8 ±69.8
(14–310); 99
Stage 4 (min.–max.); med.2613.3 ±20.0
(1–70); 5
Gaseous (min.–max.); med.6066.8 ±6.4
(48–84); 93.1

[i] MES – microembolic signals.

Figure 1

Distribution of microembolic signals (MES) over individual stages of the procedure

/f/fulltexts/AOMS/40491/AMS-16-6-40491-g001_min.jpg

Evaluation of lesions in the white matter using the Fazekas scale at baseline and at 12 months of follow-up. The mean period between the 1st MRI and ablation: 2.8 ±1.15 months; between ablation and the follow-up MRI: 10.4 months (9–11). The mean score on FS for the whole group before ablation was: 0.87 ±0.7 (0–3, med. 1); after ablation: 0.93 ±0.71 (0–3, med. 1) (Figures 2, 3). Pre-ablation examination most often presented lesions that were not very advanced, scoring up to 1 point (71 patients, 95.7%). In 3 (4.3%) patients the lesions worsened (incrementing by 1 point in each patient) during the follow-up period. All lesions were asymptomatic. In 2 patients with worsening lesions of vascular origin, MES were recorded during ablation; these were gaseous and in the amount of 58 and 194.

Figure 2

Vascular lesions in the Fazakas scale 1 grade

/f/fulltexts/AOMS/40491/AMS-16-6-40491-g002_min.jpg
Figure 3

Vascular lesions in the Fazekas scale 3 stage

/f/fulltexts/AOMS/40491/AMS-16-6-40491-g003_min.jpg

Evaluation of neurological status at baseline and at 12 months of follow-up

During ablation, one patient reported a headache during stages 2 and 3; 1 patient reported a vision disorder that resolved within < 1 min (septal puncture); the remaining patients did not report any neurological symptoms during the procedure.

None of the patients revealed a symptomatic cardiovascular event during the follow-up period and no changes were observed in patients’ neurological statuses.

Discussion

The most important results of our study were as follows: MES are generated during PVI in the majority of patients. Most often, MES are gaseous in nature. Despite the occurrence of MES, PVI seems to be clinically safe. MES do not cause any chronic morphological damage to the nervous tissue visible in MRI of the head or any changes in the neurological and functional status of patients in the follow-up. The majority of MES appear during trans-septal puncture and directly after PVI. Based on the above information, the MES associated with PVI in most cases probably result from the technical aspects of the procedure and can occur during its various stages.

It has been shown in animal studies that during the introduction of a ring catheter the air forced into the left atrium through the septal sheath is the source of gaseous MES [7, 8, 16, 24]. Due to their unsteady structure and the ability to dissolve in the plasma, gaseous MES are rarely the cause of nerve tissue damage [16]. Although a significant amount of gaseous MES can be generated within a short amount of time, their gaseous nature can probably explain the lack of symptoms. It seems, therefore, that most MES occur as a result of “iatrogenic gas injection”. Another possible source of MES may be particulate debris (coagulum). Tissue overheating is also significant during the procedure. During ablation, German authors observed mainly equivocal and solid MES, these being also mostly asymptomatic [1]. Since those who qualified for ablation are patients free from thrombus, which is always verified in the TEE before PVI treatment, it should be ruled out that MES are formed with the embolic material generated from a “chronic” intracardiac thrombus. It is difficult to entirely exclude the presence of such material in other parts of the circulatory system in patients with AF. However, it should be emphasized that in our study population there were no patients with symptoms of heart failure or impaired left ventricular ejection fraction, which further limits the risk of a cardiogenic cause of embolism. On the other hand, it is worth considering that patients with AF are characterized by a state of endogenous hypercoagulability. The presence of micro-thrombi may result from coagulopathy. Potentially enhanced endogenous anticoagulant activity and the “consumption” of C and S proteins consequently lead to impaired anticoagulant protection [25]. Additionally, the activation of inflammatory processes may be of some importance. Our earliest observations indicated that the maneuvers in the left atrial immediately preceding PVI are associated with a pronounced inflammatory response, while the latter is exclusively related to impaired fibrinolysis [26].

To date, DWI has been used to evaluate cerebral lesions of vascular origin in patients after ablation in the peri-procedural period. It is worth emphasizing that this method facilitates visualization of ischemic foci within a few minutes of their onset. It is currently known that not every focus which occurs in DWI will evolve into a chronic ischemic focus. With DWI, ultra-acute lesions are visualized at the stage of cytotoxic edema caused by ischemia, and acute lesions are visualized after ischemic damage to the blood-brain barrier. According to the results of neuroimaging studies, acute lesions of vascular origin develop during ablation in < 20% of patients. Such lesions therefore serve as a radiological marker of MES. However, it has not been established whether they undergo further changes typical of stroke lesions. It was demonstrated that lesions > 10 mm occurring in the peri-procedural period are still present after > 12 weeks, which may indicate that their effect on the nervous tissue lasts longer [6]. A comparative assessment of brain structures before and after ablation in the present study enabled us to analyze the potential evolution of the lesions of vascular origin and allowed us to assess the real burden associated with the procedure. Only 4% of patients demonstrated progression of vascular lesions associated with short peri-procedural or later periods. It is difficult to precisely indicate the time of when the new lesions occur. Symptomatic and asymptomatic foci of damage to the nervous tissue appear in patients with AF. None of our patients experienced a clinical neurological event; only a repeated MRI revealed the presence of new chronic radiological lesions. For this study, we chose a rather homogeneous group of patients, with a low average risk of embolism during the follow-up period, in order to eliminate the causes of embolic events other than those potentially associated with ablation.

Although most authors on the subject have failed to show any correlation between the quality of lesions in MRI and the number of MES, there are some opposing data [3, 5, 6].

Some authors suggest a cause-and-effect relationship between MES during ablation and cognitive disorders of varying severity. Verbal memory disorders were observed in the 3-month period following irrigated RF PVI [10]. However, these events were not confirmed in the MACPAF study [27]. The results of long-term follow-up are inconsistent in relation to the potential effect of MES during ablation on the intellectual deterioration [1, 3, 9, 28, 29]. Varying study protocols may have caused discrepancies in the results. Other parameters interfering with the results are also important; these include a concomitant intellectual dysfunction of a different etiology, older age and AF with clinically silent strokes [16, 30]. We enrolled patients with no cognitive or motor deficits in order to eliminate the influence of other potential parameters. We did not find any lesions in the above areas, which is consistent with the results of a radiological analysis related to our patients. The results of this study suggest that MES during ablation are associated with the technical aspects of the procedure and do not correspond to the burden of clinical embolism related to the procedure. MES monitoring does not allow us to determine the actual risk of cardiogenic cerebral embolism associated with ablation. The causes of cerebral ischemia in patients with cardiovascular diseases are multifactorial and differ among individual patients with atrial fibrillation. They are dependent on the clinical and pharmacological profile of the patient [31, 32]. The study’s advantage was a standardized anticoagulant treatment using VKA with INR in therapeutic ranges. Patients were prepared for AF ablation by optimal anticoagulation according to the valid guidelines [33]. We did not study patients with non-vitamin K antagonist oral anticoagulants (NOAC), but in this case, it allowed us to objectify the results obtained [33]. The assessment of ablation safety in the aspect of potential damage to the nervous system during the procedure becomes more important when various methods of this procedure are available [34].

We are aware of some limitations of our study. The most important are as follows: unilateral detection of embolic signals (technical aspects of device), non-unified method for PVI (both RF ablation and balloon cryoablation), and a rather small group of patients without a control group. However, our research paper is the first reporting the results of a planned large clinical group. To evaluate the cognitive status we used a test of low sensitivity, but it is validated, well-known, and popular in clinical practice.

In conclusion, the majority of cerebral microembolism generated during PVI are gaseous in nature. The cerebral microembolisms associated with PVI probably result from the technical aspects of the procedure and do not cause either permanent brain damage in the radiological investigation or neurological deficit.

Conflict of interest

The authors declare no conflict of interest.

References

1 

von Bary C, Deneke T, Arentz T, et al. , authors. Online measurement of microembolic signal burden by transcranial Doppler during catheter ablation for atrial fibrillation – results of a multicenter trial. Front Neurol. 2017. 8:p. 131

2 

Kuck KH, Brugada J, Fürnkranz A, et al. , authors. FIRE AND ICE Investigators. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med. 2016. 374:p. 2235–45

3 

Kochhäuser S, Lohmann HH, Ritter MA, et al. , authors. Neuropsychological impact of cerebral microemboli in ablation of atrial fibrillation. Clin Res Cardiol. 2015. 104:p. 234–40

4 

Cappato R, Calkins H, Chen SA, et al. , authors. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation. 2005. 111:p. 1100–5

5 

Gaita F, Leclercq JF, Schumacher B, et al. , authors. Incidence of silent cerebral thromboembolic lesions after atrial fibrillation ablation may change according to technology used: comparison of irrigated radiofrequency, multipolar nonirrigated catheter and cryoballoon. J Cardiovasc Electrophysiol. 2011. 22:p. 961–8

6 

Herrera Siklódy C, Deneke T, Hocini M, et al. , authors. Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: comparison of different atrial fibrillation ablation technologies in a multicenter study. J Am Coll Cardiol. 2011. 58:p. 681–8

7 

Haines DE, Stewart MT, Dahlberg S, et al. , authors. Microembolism and catheter ablation I: a comparison of irrigated radiofrequency and multielectrode-phased radiofrequency catheter ablation of pulmonary vein ostia. Circ Arrhythm Electrophysiol. 2013. 6:p. 16–22

8 

Kiss A, Nagy-Baló E, Sándorfi G, Edes I, Csanádi Z , authors. Cerebral microembolization during atrial fibrillation ablation: comparison of different single-shot ablation techniques. Int J Cardiol. 2014. 174:p. 276–81

9 

Newman SP, Harrison MJ , authors. Coronary-artery bypass surgery and the braIn: persisting concerns. Lancet Neurol. 2002. 1:p. 119–25

10 

Schwarz N, Kuniss M, Nedelmann M, et al. , authors. Neuropsychological decline after catheter ablation of atrial fibrillation. Heart Rhythm. 2010. 7:p. 1761–7

11 

Schrickel JW, Lickfett L, Lewalter T, et al. , authors. Incidence and predictors of silent cerebral embolism during pulmonary vein catheter ablation for atrial fibrillation. Europace. 2010. 12:p. 52–7

12 

Wieczorek M, Lukat M, Hoeltgen R, et al. , authors. Investigation into causes of abnormal cerebral MRI findings following PVAC duty-cycled, phased RF ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2013. 24:p. 121–8

13 

Nagy-Baló E, Tint D, Clemens M, et al. , authors. Transcranial measurement of cerebral microembolic signals during pulmonary vein isolation: a comparison of two ablation techniques. Circ Arrhythm Electrophysiol. 2013. 6:p. 473–80

14 

Nagy-Balo E, Kiss A, Condie C, Stewart M, Edes I, Csanadi Z , authors. Predictors of cerebral microembolization during phased radiofrequency ablation of atrial fibrillation: role of the ongoing rhythm and the site of energy delivery. Pacing Clin Electrophysiol. 2014. 37:p. 1436–41

15 

Bittner A, Mönnig G, Zellerhoff S, et al. , authors. Randomized study comparing duty-cycled bipolar and unipolar radiofrequency with point-by-point ablation in pulmonary vein isolation. Heart Rhythm. 2011. 8:p. 1383–90

16 

Miyazaki S, Watanabe T, Kajiyama T, et al. , authors. Thromboembolic risks of the procedural process in second-generation cryoballoon ablation procedures: analysis from real-time transcranial doppler monitoring. Circ Arrhythm Electrophysiol. 2017. 10:p. e005612

17 

Wieczorek M, Hoeltgen R, Brueck M , authors. Does the number of simultaneously activated electrodes during phased RF multielectrode ablation of atrial fibrillation influence the incidence of silent cerebral microembolism? Heart Rhythm. 2013. 10:p. 953–9

18 

Demir GG, Güneş HM, Seker M, et al. , authors. Is the presence of left atrial diverticulum associated with recurrence in patients undergoing catheter ablation for atrial fibrillation? Arch Med Sci Atheroscler Dis. 2019. 4:p. e25–31

19 

Ringelstein EB, Droste DW, Babikian VL, et al. , authors. Consensus Committee of the Ninth International Cerebral Hemodynamic Symposium. Basic identification criteria of Doppler microembolic signals. Stroke. 1995. 26:p. 1123

20 

Consensus on microembolus detection by TCD , author. International Consensus Group on Microembolus Detection. Stroke. 1998. 29:p. 725–9

21 

Lao AY, Sharma VK, Tsivgoulis G, et al. , authors. Detection of right-to-left shunts: comparison between the International Consensus and Spencer Logarithmic Scale criteria. J Neuroimaging. 2008. 18:p. 402–6

22 

Pantoni L, Basile AM, Pracucci G, et al. , authors. Impact of age-related cerebral white matter changes on the transition to disability: the LADIS study: rationale, design and methodology. Neuroepidemiology. 2005. 24:p. 51–62

23 

Norris D, Clark MS, Shipley S , authors. The mental status examination. Am Fam Physician. 2016. 94:p. 635–41

24 

Takami M, Lehmann HI, Parker KD, Welker KM, Johnson SB, Packer DL , authors. Effect of left atrial ablation process and strategy on microemboli formation during irrigated radiofrequency catheter ablation in an in vivo model. Circ Arrhythm Electrophysiol. 2016. 9:p. e003226

25 

Negreva M, Georgiev S, Vitlianova K , authors. Decreased activity of the protein C anticoagulant pathway in the early hours of paroxysmal atrial fibrillation. Clin Appl Thromb Hemost. 2017. 23:p. 793–9

26 

Wybraniec MT, Wieczorek J, Woźniak-Skowerska I, et al. , authors. Atrial fibrillation and rapid atrial pacing are linked to enhanced inflammation and altered fibrinolysis in patients undergoing pulmonary vein isolation. Kardiol Pol. 2019. 77:p. 386–8

27 

Herm J, Fiebach JB, Koch L, et al. , authors. Neuropsychological effects of MRI-detected brain lesions after left atrial catheter ablation for atrial fibrillation: long-term results of the MACPAF study. Circ Arrhythm Electrophysiol. 2013. 6:p. 843–50

28 

Browndyke JN, Moser DJ, Cohen RA, et al. , authors. Acute neuropsychological functioning following cardiosurgical interventions associated with the production of intraoperative cerebral microemboli. Clin Neuropsychol. 2002. 16:p. 463–71

29 

Medi C, Evered L, Silbert B, et al. , authors. Subtle post-procedural cognitive dysfunction after atrial fibrillation ablation. J Am Coll Cardiol. 2013. 62:p. 531–9

30 

Wieczorek J, Mizia-Stec K, Lasek-Bal A, et al. , authors. CHA2DS2-Vasc score, age and body mass index as the main risk factors of hyperintense brain lesions in asymptomatic patients with paroxysmal non-valvular atrial fibrillation. Int J Cardiol. 2016. 215:p. 476–81

31 

Kotlęga D, Gołąb-Janowska M, Meller A, et al. , authors. Beneficial effects of pre-stroke statins use in cardioembolic stroke patients with atrial fibrillation: a hospital-based retrospective analysis. Arch Med Sci. 2019. 15:p. 385–92

32 

Ying C, Wang S, Lu Y, et al. , authors. Glucose fluctuation increased mesangial cell apoptosis related to AKT signal pathway. Arch Med Sci. 2019. 15:p. 730–7

33 

Calkins H, Hindricks G, Cappato R, et al. , authors. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2018. 20:p. 1–160

34 

Koźluk E, Piątkowska A, Rodkiewicz D, Peller M, Kochanowski J, Opolski G , authors. Direct results of a prospective randomized study comparing ablation with the nMARQ catheter and the PVAC catheter used with and without a 3D system (MAPER 3D Study. Arch Med Sci. 2019. 15:p. 78–85

Copyright: © 2020 Termedia & Banach. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe